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The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel adopted a new approach to the
classiﬁcation of patients for therapeutic purposes based on the recognition of intrinsic biological subtypes within the
breast cancer spectrum. For practical purposes, these subtypes may be approximated using clinicopathological rather
than gene expression array criteria. In general, systemic therapy recommendations follow the subtype classiﬁcation.
Thus, ‘Luminal A’ disease generally requires only endocrine therapy, which also forms part of the treatment of the
‘Luminal B’ subtype. Chemotherapy is considered indicated for most patients with ‘Luminal B’, ‘Human Epidermal
growth factor Receptor 2 (HER2) positive’, and ‘Triple negative (ductal)’ disease, with the addition of trastuzumab in
‘HER2 positive’ disease. Progress was also noted in deﬁning better tolerated local therapies in selected cases without
loss of efﬁcacy, such as accelerated radiation therapy and the omission of axillary dissection under deﬁned
circumstances. Broad treatment recommendations are presented, recognizing that detailed treatment decisions need
to consider disease extent, host factors, patient preferences, and social and economic constraints.
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introduction
It is no longer tenable to consider breast cancer as a single
disease. Subtypes can be deﬁned by genetic array testing [1–3]
or approximations to this classiﬁcation using
immunohistochemistry [4–7]. These subtypes have different
epidemiological risk factors [8, 9], different natural histories
[10–12], and different responses to systemic and local therapies
[13–17]. These differences imply that clinicians managing
breast cancer should consider cases within the various distinct
subtypes in order to properly assess the relevant evidence and
arrive at appropriate therapeutic advice.
St Gallen 2011: news and progress
The 12th International Breast Cancer Conference in March
2011 brought together some 4300 participants from 96
countries and a worldwide faculty representing all relevant
disciplines. After presentation of recent research ﬁndings,
a 51-member Expert Panel (see Appendix 1) considered
a number of questions in order to arrive at treatment
recommendations for the immediate future. As in previous St
Gallen conferences [18], the Panel was charged with assessing
the evidence, but also advising on the basis of expert opinion
on those questions where the evidence was ambiguous or
lacking. For the ﬁrst time, this conference included an explicit
approach to management of conﬂicts of interest (see
Appendix 2).
Evidence was presented to support a less aggressive approach
to axillary surgery in deﬁned circumstances and the use of more
convenient equally effective approaches to radiation therapy.
For systemic therapy, the emphasis of this year’s consensus was
to reach recommendations within each of the biological
subtypes, since these already incorporate many of the risk
factors and response predictors previously considered
separately. Disease extent, host factors, patient preferences, and
economic and social factors inevitably impact the choice and
delivery of care. In general, the recommendations are intended
to guide therapy considerations outside clinical trials in
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noting where possible the availability of alternatives, which
might be only marginally less effective but less expensive.
This report will ﬁrst review the new ﬁndings presented at the
meeting (Table 1) and then proceed to summarize the
deliberations of the Panel, bringing these together to form
broad therapy recommendations.
local therapies
New results from clinical trials supported the safety of omitting
axillary dissection not only in patients with a negative sentinel
node biopsy [19] but also in patients with a clinically node-
negative axilla but pathological macrometastatic involvement
of one or two sentinel nodes in the context of breast-conserving
surgery with tangential ﬁeld radiation therapy [20]. This
continues a trend of reduced surgical extent without loss of
efﬁcacy, which dates back to the breast-conserving approaches
pioneered by Veronesi [74] and Fisher [75].
Similarly, recent studies in radiation therapy have
demonstrated the safety and efﬁcacy of abbreviated schedules
for improved patient convenience and the use of partial breast
irradiation (PBI) under certain deﬁned circumstances. These
ﬁndings are summarized in Table 1.
breast cancer subtypes
Analysis of gene expression arrays has resulted in the
recognition of several fundamentally different subtypes of
breast cancer [1]. Because it is not always feasible to obtain gene
expression array information, a simpliﬁed classiﬁcation, closely
following that proposed by Cheang et al. [7], has been adopted
as a useful shorthand. Subtypes deﬁned by clinicopathological
criteria are similar to but not identical to intrinsic subtypes and
represent a convenient approximation. As summarized in
Table 2, this approach uses immunohistochemical deﬁnition of
estrogen and progesterone receptor, the detection of
overexpression and/or ampliﬁcation of the human epidermal
growth factor receptor 2 (HER2) oncogene, and Ki-67 labeling
index, a marker of cell proliferation, as the means of identifying
tumor subtypes.
Clearly, this clinicopathological classiﬁcation requires the
availability of reliable measurements of its individual
components. Guidelines have been published for estrogen and
progesterone receptor determination [76] and for the
detection of HER2 positivity [77]. For clinical decision
making, the Panel supported using the US Food and Drug
Administration deﬁnition of HER2 positivity based on the
eligibility criteria for HER2 status determination from the
pivotal clinical trials [80, 81]. It was noted that clariﬁcations
to the ASCO/CAP guidelines were in preparation, and these
have subsequently been published [82]. Ki-67 labeling index
presents more substantial challenges, but important guidelines
for this test are under development [7, 83–85]. In the
proposed classiﬁcation, Ki-67 labeling index is chieﬂy
important in the distinction between ‘Luminal A’ and
‘Luminal B (HER2 negative)’ subtypes. If reliable Ki-67
labeling index assessment is not available, some alternative
measure of proliferation such as a histological grade may be
used in making this distinction.
panel deliberations
More than 100 questions were circulated and agreed among
Panel members before the meeting. These were presented
during the ﬁnal session of the conference. Panel members had
the opportunity to comment, and then voted electronically
either yes or no on each question, with the option to abstain
if they felt uninformed or conﬂicted. The detailed votes
are not presented here: Rather, verbal descriptions of the
extent of agreement or disagreement are given in the
following sections.
axillary surgery
T h eP a n e lw a sc l e a r l yo ft h ev i e wt h a tt h er o u t i n eu s eo f
immunohistochemistry to look for low-volume metastatic
disease in sentinel nodes was not indicated, since metastases
shown only by immunohistochemistry would not alter
management. Furthermore, isolated tumor cells, and even
metastases up to 2 mm (micrometastases) in a single sentinel
node, were not considered to constitute an indication for
axillary dissection regardless of the type of breast surgery
carried out. The Panel accepted the option of omitting axillary
dissection for macrometastases in the context of lumpectomy
and radiation therapy for patients with clinically node-
negative disease and 1–2 positive sentinel lymph nodes as
reported from ACOSOG trial Z0011 with a median follow-up
of 6.3 years [20]. The Panel, however, was very clear that this
practice, based on a speciﬁc clinical trial setting, should not be
extended more generally, such as to patients undergoing
mastectomy, those who will not receive whole-breast
tangential ﬁeld radiation therapy, those with involvement of
more than two sentinel nodes, and patients receiving
neoadjuvant therapy.
radiation therapy
The Panel considered accelerated whole-breast radiotherapy to
be an acceptable option in select patients: In particular, the
Panel was divided about the use of this approach in the
presence of extensive vascular invasion.
Partial breast irradiation (PBI) as deﬁnitive treatment in
selected patients was supported by almost half of the Panel and
by a strong majority for patients above the age of 70. There was
considerable uncertainty about its use in lymphoma survivors
who had previously undergone mantle ﬁeld irradiation, where
out-of-quadrant second cancers’ risks are considerable and for
any patient groups different from the current eligible population
in PBI trials. The Panel generally accepted PBI as an alternative to
conventional external beam boost to the tumor bed.
Post-mastectomy radiation therapy was strongly supported
for patients with four or more axillary lymph nodes involved.
While not in general favoring irradiation for those with lesser
nodal involvement, the Panel by a slim majority favored
post-mastectomy radiation for patients younger than 45 years
with 1–3 positive nodes and for patients at any age with
extensive vascular invasion in two or more blocks in
conjunction with 1–3 positive nodes.
A majority of the Panel supported radiation after complete
excision of ductal carcinoma in situ (DCIS) but was prepared to
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patient care
Field or Treatment Status of research/implications for patient care
Surgery—axillary nodes Several studies have underlined the safety of more conservative
approaches to the surgery of the axilla. If sentinel lymph nodes are
clear, axillary dissection can be omitted [19]. The ACOSOG trial Z0011
for patients with a clinically node-negative axilla who underwent
lumpectomy and tangential whole-breast irradiation showed at a
median follow-up of 6.3 years that axillary dissection can be omitted
without adversely affecting prognosis even in the presence of one or
two positive sentinel nodes [20].
Radiation therapy—partial breast irradiation A randomized trial of targeted intraoperative radiotherapy yielded results
closely similar to conventional whole-breast irradiation [21]. It is
noteworthy that in this study, 14% of the targeted intraoperative
radiotherapy group also received external beam radiotherapy and
the median follow-up in the study is 2.5 years. A single institution
series of 1822 patients treated with breast-conserving surgery has
documented excellent local control with intraoperative electron
beam therapy in selected patients [22].
Radiation therapy—abbreviated (hypofractionated
or accelerated) whole breast
Long-term results of the Canadian randomized trial in pT1,2 N0
patients largely treated without adjuvant chemotherapy at a median
follow-up of 12 years show similar locoregional control, survival,
tolerability, and cosmesis for a 16 fraction regimen compared with a
25 fraction conventionally fractionated whole-breast radiotherapy
delivered without external beam boost [23]. Similar results have been
reported from the UK START trial at a median follow-up of 6 years
using a 15 fraction regimen [24].
PARP inhibition In the presence of tumor defects in homologous recombination DNA
repair, inhibition of the PARP enzyme system may result in ‘synthetic
lethality’ and increased cell kill [25]. This is particularly well seen in carriers
of BRCA1 and BRCA2 mutations. In such patients, single-agent PARP inhibitors,
such as olaparib, produce substantial tumor responses. Other cases of triple-negative
disease seldom respond to single-agent PARP inhibition [26]. In such patients,
DNA disrupting cytotoxic agents are being investigated in combination with PARP inhibitors.
Anti-HER2 (Human Epidermal growth
factor Receptor 2) therapies
Double inhibition of HER2 by agents with differing mechanisms of action has
been shown to be superior to single-agent therapy in neoadjuvant studies [27, 28],
a concept being tested in the postoperative adjuvant setting in the ongoing ALTTO
study. The further study of the mechanism of action of trastuzumab has clariﬁed a
role for antibody-dependent cell-mediated cytotoxicity [29].
Endocrine therapy in postmenopausal patients Direct comparison between 5 years of adjuvant exemestane and anastrozole
yielded comparable results, suggesting that exemestane provides an alternative
aromatase inhibitor for up-front use [30].
Bisphosphonates Adjuvant use of zoledronic acid did not improve disease-free survival in a broad
population in the AZURE trial [31]. Subset analysis of this study showed an
apparent beneﬁt in postmenopausal patients and no beneﬁt in premenopausal
women. By contrast, the ABCSG 12 trial showed a disease-free survival beneﬁt
associated with the use of zoledronic acid among premenopausal patients, all
of whom received GnRH analog [32]. These data raise the hypothesis that an
antitumor effect of bisphosphonates might depend upon a low estrogen
environment. This hypothesis remains to be tested in further clinical trials.
Intrinsic breast cancer subtypes Deﬁnition of intrinsic subtypes has proved efﬁcient in deﬁning prognosis for
breast cancer patients [33]. Currently, there are no data from phase III trials on
their role as predictive tools for chemotherapy beneﬁt. Gene expression arrays
are reproducible and quantitative, but cost considerations limit their wide
availability. An approximation of gene expression array results is now possible
using formalin-ﬁxed parafﬁn-embedded material [7].
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Field or Treatment Status of research/implications for patient care
Molecular mechanisms predicting
chemotherapeutic response
Proliferative or immune signatures are associated with good chemotherapy
response [34–37]. In neoadjuvant therapy, a stromal signature is associated
with a reduced response, while a lymphocytic inﬁltrate predicts for a higher
response rate [38, 39].
Multiple targets for successful treatments The large and growing number of agents targeting speciﬁc mutations suggests
the eventual need for individual mutational analysis of each tumor to select a
combination of agents to block multiple pathways [40].
Overcoming resistance to endocrine therapies An improved understanding of the mechanisms of endocrine therapy resistance
includes the role of growth factors, integrins, stress kinases, and molecular
pathways including PI3K/AKT and MEK/MAPK [41]. Overcoming endocrine
therapy resistance may, therefore, require inhibition of multiple escape pathways
selected by biopsy of resistant tumors to conﬁrm the mechanisms of resistance,
which are active in each.
Treatment of germline genetic predisposition Of the 394 genes, which have been causally implicated in human cancer, some 10%
are transmitted in the germline leading to increased susceptibility [42]. Of these, the
BRCA1 and BRCA2 have been best studied, but others include TP53, PTEN, and
CDH1, all of which can increase the risk of breast cancer. BRCA1- and
BRCA2-associated breast cancer is sensitive to cross-linking agents such as cisplatin
[43], but data from randomized comparisons with standard chemotherapy agents are awaited.
Host factors and cancer risk Host factors including obesity and hyperinsulinemia are associated with increased
risk of breast cancer and recurrence of breast cancer. Retrospective studies indicate
that diabetic patients receiving metformin have a lower incidence of cancer
compared with diabetic patients not receiving this agent [44].
Vitamins and antioxidants Treatment with beta carotene, vitamin A, and vitamin E may increase mortality.
The potential role of vitamin C and selenium on mortality remains inconclusive [45].
Fenretinide showed reduced breast cancer incidence in young women [46].
The relationship between vitamin D levels and breast cancer risk or prognosis
is controversial [46].
Endocrine effects of cytotoxic drugs A recent analysis of the NSABP B-30 [47] conﬁrmed previous observations from
IBCSG 13-93 [48] that amenorrhea following chemotherapy was associated
with substantial beneﬁt in disease-free survival. On reanalysis of the NSABP
trial using the landmark method, as in the IBCSG study, this effect was
limited to the subset of patients with estrogen receptor-positive disease [49].
Modulation of angiogenesis The early promise of the use of bevacizumab in metastatic breast cancer seen
in the E2100 study has not translated into a survival beneﬁt in subsequent
studies: A synthesis of these results suggests no overall survival beneﬁt [50].
This has led the US Food and Drug Administration to reconsider its accelerated
approval of bevacizumab in breast cancer.
Studies of lipotransfer have demonstrated the potential for a stromal interaction to
stimulate vessel formation, raising the possibility that obesity might have an adverse
prognostic impact in cancer patients via a similar stromal interaction [51].
Stem cells Studies of mammary stem cells suggest a synergistic role for progesterone and
RANK ligand in tumor formation [52]. This raises the possibility of an additional
mechanism of action of clinically available RANK ligand antagonists such as denosumab [53].
Further studies of mouse mammary stem cells demonstrated that they are highly responsive
to steroid hormone signaling though they lack both estrogen and progesterone receptors.
This is thought to be mediated through paracrine signaling involving RANK
ligand [54].
Micro RNAs and their inﬂuence on tumor
growth and inhibition
Micro RNAs are involved in different biopathological features of breast cancer.
MER221 and MER222 are involved in resistance and response to endocrine agents,
while MER205 is an oncosuppressor able to interfere with response to tyrosine
kinase inhibitors of the HER family [55].
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Immunity and autoimmunity Tumor-inﬁltrating regulatory T cells stimulate mammary cancer metastases
through receptor activator (RANKL-RANK) signaling [56]. Tumor FOXP3
+ Treg
cells are a major source of RANKL, which stimulates the metastatic progression
of HER2-positive RANK-expressing breast cancer cells [52].
Gene-based testing The commercial scores from assays such as Oncotype DX  [57] and Mamma
Print  [58] have been used to determine prognosis. Oncotype DX  has been shown to
predict chemotherapy beneﬁt among patients with hormone receptor-positive disease.
An interesting STEPP analysis [59] from the adjuvant trastuzumab NSABP B-31 trial
examined the degree of HER2 mRNA expression and corresponding trastuzumab beneﬁt separately
for patients with estrogen receptor-positive and estrogen receptor-negative disease. The striking
ﬁnding was that among patients with estrogen receptor-positive disease, trastuzumab beneﬁt in
terms of 8-year disease-free survival was entirely conﬁned to those
with the higher levels of HER2 mRNA expression. In contrast, patients with
estrogen receptor-negative disease derived some beneﬁt from trastuzumab at all
levels of mRNA expression, though the quantitative beneﬁt was greater among
those with higher levels of HER2 [60].
Timing of adjuvant trastuzumab The North Central Cancer Treatment Group adjuvant trastuzumab study (N9831)
included a randomization between trastuzumab administered either concurrently
with or following chemotherapy. Analysis presented at the SABCS 2009 suggested a
superior disease-free survival with concurrent administration [61].
Targeted therapy in the neoadjuvant setting The NOAH study [62] showed clear improvement in breast pathological complete
remission (bpCR) rate and event-free survival at 3 years with neoadjuvant trastuzumab for
patients with HER2-positive disease.
Anti-HER2 therapy without chemotherapy Studies in metastatic breast cancer and in the neoadjuvant setting have
demonstrated activity of trastuzumab and other anti-HER2 agents without chemotherapy
[63] albeit usually less than the activity seen for the combination with chemotherapy.
There are no corresponding data in the adjuvant setting. However, it may be logical to
propose that anti-HER2 therapy, alone or with endocrine therapy if appropriate,
may be effective in patients who for various reasons cannot receive cytotoxic therapy [64, 65].
Neoadjuvant platinums in
triple-negative (ductal) disease
Triple-negative breast cancer includes cases susceptible to DNA-damaging agents
such as cisplatin. Neoadjuvant studies including cisplatin have produced pCR rates
between 22% and 40% among unselected triple-negative cases [66, 67], while 10 of 12
cases with BRCA1 mutations achieved pCR with single agent cisplatin [68].
End points in neoadjuvant therapy Failure to achieve pCR among patients with rapidly proliferating tumors identiﬁes a
group with a poor prognosis, which may be suitable for early trials of investigational agents [11].
Patients with small tumors in the
absence of other risk factors
A historical cohort of patients, who did not receive adjuvant systemic therapy in the
Danish Breast Cancer Group, were compared with the general Danish
population to ascertain mortality ratios associated with the diagnosis of breast
cancer. In the absence of other risk factors, patients aged 50 years and older with
small (1–10 mm) breast cancers had a risk of death comparable to the
background population. By contrast, younger patients with similar tumors
had a signiﬁcantly higher risk of death than the unaffected population [69].
Young patients with endocrine-responsive disease The ABCSG Trial 12 shows that premenopausal women with endocrine-responsive
disease who receive ovarian function suppression plus either tamoxifen or
anastrozole continue to experience a low risk of relapse [32].
Older patients and systemic chemotherapy The EBCTCG reported similar beneﬁt to systemic chemotherapy in all age groups
with estrogen receptor poor disease [70]. The CALGB 49907 study showed inferior
results for single-agent chemotherapy compared with standard ﬁrst generation
combination regimens [71]. The SWOG 8814 trial demonstrated an overall beneﬁt to
CAF followed by tamoxifen versus tamoxifen alone in postmenopausal patients with
endocrine-responsive disease [72], though this was seen primarily among those with
adverse biologic features such as quantitatively lower estrogen receptor levels,
involvement of four or more lymph nodes, or high 21 gene RS [14].
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with low-grade low-risk DCIS.
deﬁnition of biological subtypes
The Panel strongly supported the clinicopathological
determination of estrogen receptor, progesterone receptor,
HER2, and Ki-67 as useful for deﬁning subtypes, but did not
support the incorporation of tests for cytokeratin 5/6 or
epidermal growth factor receptor/HER1 for the determination
of ‘basal-like’ tumors for clinical decision making. The
endorsed clinicopathological criteria deﬁne a convenient
alternative to formal subtyping and are likely to be reﬁned in
the future. The Panel did not require multigene array deﬁnition
of tumor subtype, although there was acceptance of such
assays for certain indications (see below). However, the Panel
did recommend that the clinicopathological markers described
above were generally sufﬁcient to guide therapeutic choices.
selection of endocrine therapy in premenopausal
women
The Panel accepted tamoxifen alone or ovarian function
suppression plus tamoxifen as reasonable, though expressing
a preference for tamoxifen alone. In patients with
a contraindication to tamoxifen, ovarian function suppression
alone was accepted as a treatment, while the combination of
ovarian function suppression plus an aromatase inhibitor was
also considered reasonable.
selection of endocrine therapy in postmenopausal
women
The Panel was exactly equally divided about whether all
postmenopausal patients should receive an aromatase inhibitor
(if available and not contraindicated) at some point in
treatment, but was more supportive of aromatase inhibitors in
the presence of involved lymph nodes. A large majority felt that
selected patients could be treated with tamoxifen alone, and
that patients could be switched to tamoxifen if intolerant to
aromatase inhibitors. The Panel stressed the need to ensure that
patients receiving an aromatase inhibitor were indeed
postmenopausal, whether by clinical or biochemical criteria.
The Panel considered that 5 years of an aromatase inhibitor
was a sufﬁcient duration and a majority opposed extension
even in the presence of node-positive disease or among younger
postmenopausal patients (<55 years of age). The Panel was
almost unanimous in rejecting CYP2D6 testing to dictate
choice of endocrine therapy type.
chemotherapy
The Panel agreed that factors arguing for the inclusion of
chemotherapy were high histological grade, high proliferation
as measured by Ki-67, low hormone receptor status, positive
HER2 status, and ‘Triple negative’ status in invasive ductal
carcinoma of usual forms. These factors are largely captured in
the tumor subtype deﬁnitions summarized in Table 2. There
was a lack of complete consensus on the threshold indication
for inclusion of chemotherapy for patients with ‘Luminal A’ or
‘Luminal B (HER2 negative)’ disease. In terms of disease extent,
the Panel did not believe that node positivity per se was an
indication for use of chemotherapy, though a strong majority
would use it if more than three lymph nodes were involved.
Several tests are available which deﬁne prognosis [57, 58, 86].
These may indicate a prognosis so good that the doctor and
patient decide that chemotherapy is not required. A strong
majority of the Panel agreed that the 21-gene signature
(Oncotype DX ) [57] may also be used where available to
predict chemotherapy responsiveness in an endocrine-
responsive cohort where uncertainty remains after
consideration of other tests, but the majority agreed that the
chemopredictive properties of the 70-gene signature
(MammaPrint ) [58] were not yet sufﬁciently established.
Trials are ongoing to clarify this role for both tests. The
majority of the Panel did not support lymphovascular invasion
as a sufﬁcient indication for chemotherapy, and less than
a quarter of the Panel supported uPA/PAI1 [86] as a predictive
marker for the use of chemotherapy.
chemotherapy in subtypes
The Panel strongly agreed that the ‘Luminal A’ subtype was less
responsive to chemotherapy; that chemotherapy was less useful
in such patients; and that no preferred chemotherapy regimen
could be deﬁned for treatment of ‘Luminal A’ disease.
For ‘Luminal B’ disease, the Panel considered that both
anthracyclines and taxanes should be included in the
chemotherapy regimen. While the Panel could not deﬁne a single
preferred chemotherapy regimen for ‘HER2 positive’ disease, the
majority again favored the inclusion of both anthracyclines and
taxanes. For ‘Triple negative’ disease of the usual ductal type, the
Table 1. (Continued)
Field or Treatment Status of research/implications for patient care
Special histological types of breast cancer Review of special histological types in a large institutional series suggested that
endocrine-responsive types such as tubular and cribriform carcinomas may be
suitable for observation without therapy or for endocrine therapy alone. Rare
variants of lobular carcinomas (e.g. pleomorphic) and apocrine carcinomas require
treatment according to their biological features in a manner analogous to that used
for ductal carcinoma. The heterogeneous ‘Triple negative’ subtype includes adenoid
cystic, juvenile secretory (good prognosis), medullary (intermediate prognosis), and
metaplastic (either low grade, with good prognosis; or high grade, with poor prognosis)
carcinomas, for which no generalizations can be proposed [73].
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taxanes and an alkylating agent (typically cyclophosphamide),
but did not support the routine use of cisplatin or carboplatin. A
slim majority agreed that dose-dense chemotherapy [87] should
be considered for such patients, and the Panel was strongly
opposed to the inclusion of antiangiogenic therapies at this time,
while noting that further trials are ongoing.
trastuzumab
The Panel unanimously supported the use of 1 year of
trastuzumab as standard adjuvant treatment for patients with
‘HER2 positive’ disease, and the majority were willing to extend
this to patients with pT1b, but not pT1a pN0 disease.
Trastuzumab administered for <1 year [88] was regarded as
suboptimal if 1 year of therapy was feasible, but better than no
trastuzumab if limited resources prevented its full duration use.
While awaiting data from the ongoing HERA trial, the Panel did
not support continuation of adjuvant trastuzumab beyond 1
year.Whilepreferringthattrastuzumabbeinitiatedconcurrently
with chemotherapy, the Panel also accepted its sequential use.
The Panel did not support the use of trastuzumab without
chemotherapyifchemotherapycouldbegiven,butwasprepared
to countenance such treatment in circumstances where
chemotherapy could not be delivered.
neoadjuvant cytotoxic therapy
A majority of the Panel considered that neoadjuvant cytotoxic
therapy was of value beyond its role in facilitating conservative
surgery and noted the improved prognostic information
associated with pathological complete response to such therapy,
particularly in patients with ‘HER2 positive’ and ‘Triple
negative (ductal)’ tumors [89], which may allow earlier change
from an ineffective regimen.
The Panel considered that the choice of neoadjuvant
chemotherapy should be made on the same basis as applied in
the selection of postoperative adjuvant treatments. The Panel
supported the incorporation of an anti-HER2 drug in the
neoadjuvant therapy for patients with ‘HER2 positive’ disease,
but did not support dual HER2 targeting at this point in time.
The Panel did not support cytotoxic neoadjuvant therapy for
tumors with low proliferation or high endocrine responsiveness.
neoadjuvant endocrine therapy
The Panel was almost unanimous in supporting the use of
neoadjuvant endocrine therapy as an option for postmenopausal
patients with highly endocrine-responsive disease. If given, the
Panel considered that such treatment should be continued until
maximal response or for a minimum of 4–8 months.
bisphosphonates
The Panel did not support the use of bisphosphonates for
antitumor effect in either pre- [32] or postmenopausal [90]
patients.
male breast cancer
Adjuvant tamoxifen was strongly supported, but only a slim
majority would consider aromatase inhibitors in patients with
Table 2. Surrogate deﬁnitions of intrinsic subtypes of breast cancer (4, 7)
Intrinsic Subtype (1) Clinico-pathologic deﬁnition Notes
Luminal A ‘Luminal A’ This cut-point for Ki-67 labelling index was established by comparison
with PAM50 intrinsic subtyping (7). Local quality control of Ki-67
staining is important.
ER and/or PgR positive(76)
HER2 negative (77)
Ki-67 low (<14%)
*
Luminal B
** ‘Luminal B (HER2 negative)’ Genes indicative of higher proliferation are markers of poor prognosis in multiple
genetic assays (78). If reliable Ki-67 measurement is not available, some alternative
assessment of tumor proliferation such as grade may be used to distinguish
between ‘Luminal A’ and ‘Luminal B (HER2 negative)’.
ER and/or PgR positive
HER2 negative
Ki-67 high
‘Luminal B (HER2 positive)’ Both endocrine and anti-HER2 therapy may be indicated.
ER and/or PgR positive
Any Ki-67
HER2 over-expressed or ampliﬁed
Erb-B2 overexpression ‘HER2 positive (non luminal)’
HER2 over-expressed or ampliﬁed
ER and PgR absent
‘Basal-like’ ‘Triple negative (ductal)’ Approximately 80% overlap between ‘triple negative’ and intrinsic ‘basal-like’ subtype
but ‘triple negative’ also includes some special histological types such as (typical)
medullary and adenoid cystic carcinoma with low risks of distant recurrence.
ER and PgR absent
HER2 negative
Staining for basal keratins (79) although shown to aid selection of true
basal-like tumors, is considered insufﬁciently reproducible for general use.
*This cut-point is derived from comparison with gene array data as a prognostic factor [7]. Optimal cut-points in Ki-67 labelling index for prediction of
efﬁcacy of endocrine or cytotoxic therapy may vary.
**Some cases over-express both luminal and HER2 genes.
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did not support extended endocrine treatment beyond 5 years
for male breast cancer. The lack of any evidence on these latter
two points was acknowledged.
summary of systemic treatment recommendations
The approach to treatment within breast cancer subtypes
greatly simpliﬁes the deﬁnition of therapy indications, since the
subtypes themselves incorporate many of the risk and
predictive factors used in previous consensus
recommendations. The broad recommendations are
summarized in Table 3 and essentially indicate endocrine
therapy alone for patients with clinicopathologically classiﬁed
‘Luminal A’ disease (except in deﬁned high-risk cases), chemo-
endocrine therapy for ‘Luminal B’, the addition of anti-HER2
therapy in the presence of ‘HER2 positivity’, and a reliance on
chemotherapy for most patients with ‘Triple negative’ disease
(e.g. those with invasive ductal carcinoma).
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